AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02689024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Local anesthetic: amide group ATC code N01BB01
Study NCT02689024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
Study NCT02689024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
Study NCT02689024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
Study NCT02689024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
Study NCT02689024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone
Description: Analgesic drug: Pyrazolone derivate with analgetic, antipyretic and antiphlogistic properties ATC N02BB02 Usual dosage is 1000 mg t.i.d. or q.i.d. orally and intravenously
Study NCT02689024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
Study NCT02689024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Opioids: Natural opium alkaloid. Longer-acting opioid. ATC code N02AA01 Usual dosage is 0.1 mg intravenously and titrated guided by pain and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
Study NCT02689024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Local anesthetic: amide group ATC code N01BB10
Study NCT02689024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetic: amide group ATC code N01BB09
Study NCT01831999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RecoveryTrack - Extended Care (RT-E)
Description: Counselors in this condition will be trained on the RecoveryTrack-Extended Care (RT-E) web-based monitoring system so that they are able to navigate the computer application, and implement the clinical content and procedures of the intervention. Counselors will conduct monitoring and feedback sessions using RT-E for clients newly admitted to IOP over a course of eight months. If the client is not attending treatment, counselors will attempt contact over the phone and via other methods. When contacted, the counselor will conduct the RT-E assessment and, as the situation warrants, provide support to reengage the client in treatment or support recovery in other ways mentioned. HIV risk will be assessed as well, with encouragement of testing and referral to HIV specialists as needed.
Study NCT00548925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-894
Description: 6 mg BID tablets, 8 weeks of treatment
Study NCT00548925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: BID tablets, 8 weeks of treatment
Study NCT02523898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformine
Description: 1500 mg metformine 8week plus 100 mg clomiphene for 5 days
Study NCT02523898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo 8 weeks plus 100 mg clomiphene for 5 days
Study NCT02523898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration
Study NCT02523898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration
Study NCT04376710 — intervention group
Intervention type: OTHER
Intervention: Completion of pre-pandemic survey
Description: Surgeons will take a pre-pandemic survey to determine surgeon perceptions to telemedicine and barriers to implementation.
Study NCT04376710 — intervention group
Intervention type: OTHER
Intervention: Completion of survey after peak of pandemic
Description: Surgeons will take another survey after the peak of pandemic to determine surgeon perceptions to telemedicine and barriers to implementation.
Study NCT04376710 — intervention group
Intervention type: OTHER
Intervention: Completion of post telemedicine encounter survey
Description: Patients will take a post telemedicine encounter survey to determine patient perceptions to telemedicine and barriers to implementation.
Study NCT03872167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP, Intelligent automatic mode defined by assured volume with pressure support
Description: Correction of night ventilation through an automatic mode of ventilation with assured volume with pressure support
Study NCT03872167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP, manual tritration.
Description: Correction of night ventilation through a manual titration of non-invasive mechanical ventilation using polysomnography.
Study NCT03053076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood Mononuclear Cells Therapy
Description: Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for safety and effect evaluation
Study NCT03053076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: 0.9% Sodium Chloride in control group
Study NCT02793141 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered
Study NCT03661632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986310
Description: Specified dose on specified days
Study NCT03661632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT00589563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: 0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
Study NCT00589563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60mg/kg on days -5 and -4 from stem cell transplant
Study NCT00589563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 60mg/kg on day -4 from stem cell transplant
Study NCT00589563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
Study NCT00589563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Melphalan 140 mg/m2 on day -4 from stem cell transplant
Study NCT00589563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
Study NCT00589563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose.~Pediatric Patients \<40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose
Study NCT00589563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: 0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
Study NCT00589563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
Study NCT00589563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell transplantation
Description: The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
Study NCT00589563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
Study NCT00589563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
Study NCT00589563 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: 1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
Study NCT00459953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended treatment
Description: All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.
Study NCT01957553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast test product
Description: Coloplast test product is a newly developed 2-piece ostomy appliance
Study NCT01957553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura
Description: SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
Study NCT01822340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10560A
Description: Once weekly HM10560A
Study NCT01822340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: Once daily Genotropin
Study NCT01906203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: body bioelectrical impedance performed by Z-Métrix (class IIa) - BIOPARHOM 12 allée des lacs de garde, Savoie Technolac BP 238, 73374 Bourget du lac, France
Study NCT04426981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities. In the first session, participants will begin to identify domains of their life which are important to them. In the second session, participants will be assisted in creating an action plan to engage in more activities in one or more domains of importance. In session 3-8, participants will be assisted in problem solving any challenges they encountered in implementing their previous action plan and will develop a new action plan. The intervention will continue until participants achieved three action plans or reach the eight-session limit, whichever comes first.
Study NCT04334551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: switches from etravirine to doravirine, in experienced HIV patients
Study NCT03903445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids)
Description: MaPa Kids is an 8-session parenting program delivered weekly to groups of parents (N=15 per group).~The program includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behavior; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behavior, and consequences for noncompliance, rule-breaking, and aggressive behavior; 6) problem solving with children; and 7) mindfulness based stress reduction.
Study NCT03903445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens)
Description: MaPa Teens is a 9-session parenting program delivered to groups of parents and children aged 10-17 (N=15 dyads per group).~The program includes the following content: 1) one-on-one time with parents and teens, 2) positive reinforcement of positive behavior, 3) managing anger and stress, 4) establishing rules and routines, 5) family budgeting, 6) accepting responsibility for actions, 7) resolving family conflicts, 8) keeping safe in the community and resolving conflicts, and 9) reflection and moving on.
Study NCT04544254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral transversus thoracis muscle plane block
Description: The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided. Twenty milliliters bupivacaine 0.5% 1mg/body weight will be injected between internal intercostal muscle and transversus thoracis muscle on both sides.
Study NCT04544254 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: A needle will be place in the similar area to the transversus thoracis muscle plane block, but no drugs will be injected to the area
Study NCT03209687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin
Description: Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles
Study NCT04990154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a 12-week intradialytic exercise
Description: a 12-week intradialytic exercise (supine lower-limb ergometer, 30 minutes/session, 3 sessions/week)
Study NCT00737282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex 25 mg
Description: One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
Study NCT00737282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex 50 mg
Description: Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
Study NCT01275391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Screening, Brief Intervention, Referral toTreatment
Description: A computerized screening for tobacco, alcohol and drug use accompanied by 10-15 pages of health information regarding the risks of tobacco, alcohol and drug use. This is followed by a brief conversation with the primary care provider regarding the health risks of tobacco, alcohol and drug use and a referral to treatment for those at high risk of substance use problems.
Study NCT03067649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: 90-minute interview to discuss their concerns and possible barriers to seeking treatment for themselves
Study NCT03067649 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information only control
Description: Participants are provided with a pamphlet containing referral information
Study NCT01598012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ayurved Siriraj Prasaplai with or without mefenamic acid
Description: Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
Study NCT01598012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with or without mefenamic acid
Description: Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
Study NCT00719121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talarozole
Description: Topical Application (20 mg)
Study NCT00719121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Differin™, 0.1% adapalene gel
Description: Topical Application (20 mg)
Study NCT03950648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spatial Cognitive Training
Description: map reading and route-learning skills
Study NCT00007657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy
Study NCT00007657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive medical therapy
Study NCT00007657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) plus intensive medical therapy
Study NCT00191789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
Study NCT00191789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 60 mg/m\^2, IV, every 21 days x 4 cycles (1-4)
Study NCT00191789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 70 mg/m\^2, IV, every 21 days x 4 cycles (5-8)
Study NCT00191789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
Study NCT05065177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational live attenuated mumps vaccine
Description: The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
Study NCT05065177 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: control live attenuated mumps vaccine
Description: The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
Study NCT01922206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRACK Intervention
Description: TRACK Intervention~3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child
Study NCT00759811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks.
Study NCT01307800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT00759811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks.
Study NCT04399577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candida antigen
Description: Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention
Study NCT03847233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jetstream Atherectomy System
Description: A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
Study NCT03552198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternative health advice
Description: These messages targeted specific beliefs about air pollution and protective actions aimed at reducing exposure to air pollution. In addition, message specificity was targeted, which means that compared to the usual messages, the alternative messages reported more detailed health recommendations.
Study NCT02916342 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Patients will receive an ultrasound-guided interscalene brachial plexus block before general anaesthesia.
Study NCT02916342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular-axillary nerve blocks
Description: Patients will receive ultrasound-guided supraclavicular and axillary nerve blocks before general anaesthesia.
Study NCT03719976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-based educational intervention
Description: The group-based educational intervention will use a bilingual Community Health Worker (CHW) who will teach parents key skills needed to access health care for children. Parents will be invited to attend 6 small, closed-group sessions held over 12 weeks and lasting no more than 75 minutes. Sessions will be interactive, culturally-appropriate, and held in parents' preferred language.
Study NCT02972489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D OFDI guidance arm
Description: Subjects randomized to 3D-guidance arm will undergo optical frequency domain imaging (OFDI) assessment in the main vessel after re-wiring into the jailed side branch following stent implantation. If the position of the wire is not located in the optimal cell, further attempts to redirect the wire to the optimal cell will be performed, with subsequent OFDI acquisitions to confirm position in 2D and off-line 3D reconstruction. After procedure, OFDI is performed in the main branch.